SOURALOVÁ, Tereza, Pavel VENTRUBA, Michal JEŠETA, Daniela ŘEHÁKOVÁ, Aleš HAMPL and Irena KOUTNÁ. Establishment of human embryonic stem cells for stem-cell therapies. In SY-STEM 2022, Vienna, Austria. 2022.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Establishment of human embryonic stem cells for stem-cell therapies
Authors SOURALOVÁ, Tereza, Pavel VENTRUBA, Michal JEŠETA, Daniela ŘEHÁKOVÁ, Aleš HAMPL and Irena KOUTNÁ.
Edition SY-STEM 2022, Vienna, Austria, 2022.
Other information
Original language English
Type of outcome Conference abstract
Country of publisher Austria
Confidentiality degree is not subject to a state or trade secret
WWW URL
Tags International impact
Changed by Changed by: Mgr. Tereza Souralová, učo 424163. Changed: 31/5/2023 12:48.
Abstract
Human embryonic stem cells are able to differentiate into every cell type in the human body making them a tremendous cell source for regenerative medicine. However, the production of human embryonic stem cell lines for clinical use is challenging as clean rooms, highly-qualified personnel, standard operating procedures for both manufacture and quality control are required. Here we present the derivation of clinical-grade hESC lines in cooperation with the Centre of assisted reproduction - University Hospital Brno which provided 6-day old blastocysts. Laminin 521 in combination with Nutristem, Human serum albumin, and ECadherin was used for the mechanical derivation. Human embryonic stem cells were cultured on laminin 521 in a Nutristem medium. The derivation itself and subsequent culture are xeno-free, feeder-free, and fulfill standards of current good manufacturing practices. In-depth quality control provides essential information about the safety, pluripotency, and differentiation potential of lines. Presented clinical-grade hESC lines were established according to state-of-the-art technology that makes them excellent cell source for stem cell-based therapies.
Links
MUNI/A/1398/2021, interní kód MUName: Zdroje pro tkáňové inženýrství 12 (Acronym: TissueEng 12)
Investor: Masaryk University
NV18-08-00412, research and development projectName: Lidské embryonální kmenové buňky pro klinické aplikace: derivace a charakterizace
Investor: Ministry of Health of the CR
PrintDisplayed: 30/7/2024 11:21